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Background: Idiopathic pulmonary fibrosis (IPF) is a common and invariably lethal interstitial lung disease with
poorly effective therapy. Blockade of the K+ channel KCa3.1 reduces constitutive α-SMA and Smad2/3 nuclear
translocation in IPF-derived human lung myofibroblasts (HLMFs), and inhibits several transforming growth factor
beta 1 (TGFβ1)-dependent cell processes. We hypothesized that KCa3.1-dependent cell processes also regulate
the TGFβ1-dependent Smad2/3 signalling pathway in HLMFs. HLMFs obtained from non-fibrotic controls (NFC)
and IPF lungs were grown in vitro and examined for αSMA expression by immunofluorescence, RT-PCR, and flow
cytometry. Two specific and distinct KCa3.1 blockers (TRAM-34 200 nM and ICA-17043 [Senicapoc] 100 nM) were used
to determine their effects on TGFβ1-dependent signalling. Expression of phosphorylated and total Smad2/3 following
TGFβ1 stimulation was determined by Western blot and Smad2/3 nuclear translocation by immunofluorescence.
Results: KCa3.1 block attenuated TGFβ1-dependent Smad2/3 phosphorylation and nuclear translocation, and this
was mimicked by lowering the extracellular Ca2+ concentration. KCa3.1 block also inhibited Smad2/3-dependent
gene transcription (αSMA, collagen type I), inhibited KCa3.1 mRNA expression, and attenuated TGFβ1-dependent
αSMA protein expression.
Conclusions: KCa3.1 activity regulates TGFβ1-dependent effects in NFC- and IPF-derived primary HLMFs through
the regulation of the TGFβ1/Smad signalling pathway, with promotion of downstream gene transcription and
protein expression. KCa3.1 blockers may offer a novel approach to treating IPF.
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Idiopathic pulmonary fibrosis (IPF) is a common disease
that occurs primarily in older people with a prevalence
in the USA of 227 cases per 100,000 in the >75 year age
group [1,2]. In the UK, its incidence doubled between
1998 and 2003 with 4,000 new cases per year, and the in-
cidence continues to increase by 10% annually [2,3]. It
therefore represents an important cause of morbidity
and mortality, and current treatments such as pirfeni-
done are of limited efficacy [4-6].
Myofibroblasts are an attractive target for the treatment
of IPF. They are the primary effector of tissue fibrosis as* Correspondence: kmr11@le.ac.uk
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unless otherwise stated.they synthesize large quantities of collagen [1], have a con-
tractile phenotype [7-9] and are resistant to apoptosis [10].
Myofibroblast expansion occurs through the differenti-
ation of fibroblasts [11]; this involves reorganization of the
actin cytoskeleton, increased expression of alpha smooth
muscle actin (αSMA) and incorporation of actin stress fi-
bers [8]. As myofibroblasts rarely persist in healthy lungs,
their differentiation is considered a key event in the patho-
genesis of IPF.
Transforming growth factor beta 1 (TGFβ1) is a key
pro-fibrotic growth factor involved in the pathogenesis
of IPF [12-14], which stimulates fibroblast to myofibro-
blast differentiation both in vivo and in vitro [15-18].
The major TGFβ1-dependent signalling pathway in-
volves the cytoplasmic Smad proteins [19]. Activated
TGFβ1 binds to the TGFβ type II receptor (TGFβRII)
leading to the recruitment of the TGFβ type I receptor,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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targets Smad2 and Smad3. Phosphorylated Smad2 and
Smad3 then form hetero-oligomeric complexes with
Smad4 and translocate to the nucleus to regulate gene
expression through transcription and thus mediate the
biological effects of TGFβ1 such as cell growth, differen-
tiation and contraction [20-22]. In particular, this
TGFβ1/Smad pathway contributes to myofibroblast dif-
ferentiation by increasing α-smooth muscle actin expres-
sion [20,21].
Ion channels are attractive therapeutic targets in many
chronic diseases. In particular, the Ca2+ activated K+
channel KCa3.1 plays an important role in Ca
2+ signalling
through its ability to maintain a negative membrane po-
tential during cellular activation, which enhances Ca2+
influx from the extracellular fluid [23-25]. The KCa3.1
channel modulates the activity of several structural and
inflammatory cells [26-28], but more specifically, KCa3.1
blockade inhibits several TGFβ1-dependent cell pro-
cesses in primary human lung myofibroblasts (HLMFs)
derived from both non-fibrotic and IPF lung tissue [29].
Our previous work demonstrated that blocking KCa3.1
with the selective KCa3.1 blockers TRAM-34 and ICA-
17043 inhibits TGFβ1-dependent HLMF wound heal-
ing, collagen secretion, contraction and Ca2+ influx
[29]. In addition, IPF-derived HLMFs demonstrate in-
creased constitutive αSMA expression and Smad2/3
nuclear localisation, effects which are reversed by
KCa3.1 inhibition [30].
We hypothesized that KCa3.1 channel activity also
regulates TGFβ1-dependent responses in HLMFs
through the TGFβ1/Smad signalling pathway. We
therefore investigated the role of the KCa3.1 channel in
TGFβ1-dependent Smad2/3 phosphorylation, Smad2/3
nuclear translocation, gene transcription and αSMA
protein expression in HLMFs obtained from both
healthy and IPF lung.
Results
TGFβ1-dependent Smad2/3 phosphorylation is
attenuated by KCa3.1 blockade
The ability of KCa3.1 blockers to attenuate several
TGFβ1-dependent cell processes in HLMFs [29] suggests
that KCa3.1 potentially regulates the activity of TGFβ1-
dependent transcription factors. Smad2 and Smad3 are
implicated as the major factors regulating HLMF differ-
entiation and collagen secretion in response to TGFβ1
[20,21,31]. Phosphorylation is a key initial event in the
activation of these Smad proteins. Using Western blot
analysis, we therefore investigated the effect of TGFβ1
(10 ng/ml) on the phosphorylation of Smad2/3 and the
expression of total Smad2/3 in HLMFs. Phosphorylation
of Smad2/3 after TGFβ1 stimulation was examined over
a time course of 5 h and peaked at 60 min (Figure 1A).No significant differences in Smad2/3 phosphorylation
were seen between non-fibrotic controls (NFC) and IPF
data, and data were therefore pooled for statistical ana-
lysis here and elsewhere where no disease-related differ-
ences were evident. Further experiments were therefore
performed after 60-min stimulation with TGFβ1 in the
presence or absence of the highly selective KCa3.1
blockers TRAM-34 (Kd 20 nM) [24] and ICA-17043 (Kd
10 nM) [32]. TGFβ1 increased Smad2/3 phosphorylation
in both NFC and IPF-derived HLMFs (P = 0.0022, paired
t test). This was suppressed by both TRAM-34 and ICA-
17043 (P = 0.0117 and P = 0.0144, respectively, one-way
ANOVA corrected by Sidaks multiple comparisons test)
(Figure 1B, C, D).
TGFβ1-dependent Smad2/3 nuclear translocation is
disrupted by KCa3.1 inhibition
Once TGFβ1 has induced phosphorylation of Smad2/3,
this complex interacts with Smad4, which acts as a
transporter and enters the nucleus to initiate gene tran-
scription. Inhibition of Smad2/3 phosphorylation should
therefore also prevent Smad2/3 nuclear translocation.
We previously demonstrated using immunofluorescence
that total Smad2/3 nuclear staining was significantly
greater in IPF-derived HLMFs in comparison to NFC-
derived cells [30], a finding also confirmed in this study
(P = 0.0365). Here, TGFβ1 significantly increased
Smad2/3 nuclear translocation in HLMFs over untreated
control cells (P = 0.0025, paired t test) (Figure 2A, B, C,
D). No significant differences were found between
TGFβ1-stimulated NFC and IPF HLMF responses, and
therefore, statistics were performed on pooled data.
TRAM-34 (200 nM) or ICA-17043 (100 nM) signifi-
cantly attenuated the nuclear translocation of Smad2/3
(P = 0.0034 and P = 0.0029, respectively, two-way
ANOVA corrected by Sidak’s multiple comparison test).
In contrast, the structurally related molecule, TRAM-85,
which does not have channel blocking activity, did not in-
hibit nuclear translocation of Smad2/3 (Figure 2A, B, C,
D). Total Smad2/3 was examined in the nuclear fraction
and cytoplasmic extract of both NFC and IPF-derived
HMFs. Following TGFβ1-stimulation, there was signifi-
cantly greater amounts of total Smad2/3 located within
the nucleus of HLMFs (P < 0.0001); furthermore, after in-
hibition with ICA-17043 (100 nM), this increase was at-
tenuated (P = 0.0168, Figure 2E). No significant changes
were found in the cytoplasmic extract (Figure 2F). Thus,
KCa3.1 activity is critical for the TGFβ1-dependent phos-
phorylation and nuclear translocation of Smad2/3.
TGFβ1-dependent Smad2/3 phosphorylation and nuclear
translocation are Ca2+-dependent
We have shown previously that KCa3.1 channel blockade
inhibits a rise in intracellular Ca2+ in HLMFs following
Figure 1 Phosphorylation of Smad2/3 is KCa3.1 dependent. (A) Phosphorylation of Smad2/3 in HLMFs was most abundant after 60 min of
stimulation with TGFβ1 (10 ng/ml) (n = 3). (B) Representative Western blot analysis showing the increased phosphorylation of Smad2/3 after 60
min of stimulation with TGFβ1 (10 ng/ml) and its inhibition by TRAM-34 and ICA-17043. Phosphorylation of Smad2/3 was examined by fold
change over total Smad2/3 and normalized to β-actin. TGFβ1-dependent increases in phosphorylated Smad2/3 were inhibited by TRAM-34 200
nM (NFC n = 3 and IPF n = 4) (C) and by ICA-17043 100 nM (NFC n = 3 and IPF n = 3) (D). Results are represented as mean ± SEM *P < 0.05,
**P < 0.01 (repeated measures ANOVA corrected by Sidaks multiple comparison test).
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membrane depolarization which reduces Ca2+ entry
[25,29]. If this is mechanistically important, lowering
extracellular Ca2+ should also inhibit TGFβ1-dependent
Smad2/3 phosphorylation and nuclear translocation.
Myofibroblasts incubated for 1 h in Ca2+-free media
phosphorylated significantly less Smad2/3 in the pres-
ence of TGFβ1 (10 ng/ml) than those incubated in
media containing normal external Ca2+, P = 0.0439
(one-way ANOVA, corrected by Sidaks multiple com-
parison test) (Figure 3A, B). This was accompanied by
reduced TGFβ1-dependent Smad2/3 nuclear transloca-
tion in Ca2+-free media, P = 0.0114 (Figure 4A, B). Thissuggests that the enhancement of Ca2+-influx by KCa3.1
channels is an essential requirement for the efficient
TGFβ1-dependent phosphorylation and nuclear trans-
location of Smad2/3.
TGFβ1-dependent increases in αSMA, collagen type I and
KCa3.1 mRNA are inhibited following KCa3.1 channel block
Impaired TGFβ1-dependent Smad2/3 nuclear transloca-
tion with KCa3.1 blockade predicts that TGFβ1-
dependent gene transcription will also be inhibited. To
assess this, we first undertook quantitative RT-PCR to
examine the mRNA expression of αSMA and collagen
type I in HLMFs. TGFβ1 (10 ng/ml) stimulation for 24 h
Figure 2 (See legend on next page.)
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Figure 2 Smad2/3 nuclear translocation is inhibited by KCa3.1 channel blockade. (A) The ratio of nuclear to whole cell staining of Smad2/3
demonstrates a significant increase in nuclear translocation following TGFβ1 stimulation compared to control. TRAM-34 (200 nM) inhibited
TGFβ1-induced Smad2/3 nuclear translocation (NFC n = 4, IPF n = 4) whereas the structurally related molecule TRAM-85 without KCa3.1 blocking
properties did not inhibit nuclear translocation. NFC and IPF data were pooled for statistical analysis. (B) Representative fluorescent microscopy
images illustrate the increased expression of Smad2/3 following TGFβ1 stimulation and its movement into the nucleus, which was significantly
attenuated by TRAM-34 (200 nM). (C) ICA-17043 (100 nM) also significantly attenuated Smad2/3 nuclear translocation, which can be seen visually
in (D). (E) Quantification of Western blot analysis confirms that the total Smad2/3 in the nuclear enriched fraction is significantly increased following
TGFβ1 stimulation and attenuated by ICA-17043 (100 nM). Results are normalized to TATA Binding Protein (TBP) and representative Western blot
analysis images are shown. (F) Similarly, the total Smad2/3 was examined in the cytoplasmic-enriched fraction; however, no changes were found
following TGβ1 stimulation or treatment with ICA-17043 (NFC n = 2 and IPF n = 3, data pooled). Results are represented as mean ± SEM ***P < 0.001,
**P < 0.01 (two-way ANOVA corrected by Sidaks multiple comparison test), ##P < 0.0001, one sample t test, #P < 0.05, paired t test.
Figure 3 TGF 1-dependent Smad2/3 phosphorylation is Ca2+
dependent. (A) A representative Western blot demonstrating Smad
2/3 phosphorylation when cells are incubated in media either
containing Ca2+ or without. (B). Quantification of Western blots
showing that the increased phosphorylation of Smad2/3 after 60
min of TGFβ1 exposure (10 ng/ml) is largely dependent on the
presence of extracellular Ca2+. Phosphorylation of Smad2/3 was
examined by fold change over total Smad2/3 and normalized to
β-actin (NFC n = 2, IPF n = 4, data pooled for statistical analysis). HLMFs
stimulated for 1 h in Ca2+-free media phosphorylated significantly less
Smad2/3 than those incubated in media containing Ca2+. *P < 0.05,
***P < 0.001 results are represented as median (IQR) (one-way ANOVA,
corrected by Sidaks multiple comparison test).
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pression, and these increases were significantly inhibited
by both TRAM-34 (200 nM) and ICA-17043 (100 nM)
(Figure 5A, B).
KCa3.1 mRNA and functional channel expression are
also upregulated in HLMFs by TGFβ1 [29]. We were
therefore interested in whether KCa3.1 regulates its own
mRNA expression. We found that TGFβ1 also signifi-
cantly increased KCa3.1 mRNA expression within
HLMFs, and this upregulation was significantly higher in
IPF HLMFs in comparison to NFC HLMFs, as previ-
ously published [29]. This increase was also inhibited by
the KCa3.1 channel blockers TRAM-34, and ICA-17043
(P = 0.0385 and P = 0.0313, respectively, Wilcoxon-
matched pairs rank test) (Figure 5C, D). Thus, KCa3.1
channel block inhibited the transcription of several
diverse TGFβ1-regulated genes (αSMA - structural pro-
tein, collagen type I - secreted matrix protein, KCa3.1 -
ion channel), in keeping with its ability to inhibit
Smad2/3 phosphorylation and nuclear translocation.
KCa3.1 block attenuates TGFβ1-induced increases in αSMA
protein expression
We and others have shown previously that IPF-derived
HLMFs express higher levels of αSMA than NFC
HLMFs constitutively, and we showed that this is inhib-
ited by KCa3.1 blockade. Because TGFβ1-dependent
transcription of the αSMA gene is also inhibited by
KCa3.1 blockers, we proceeded to investigate the effect
of KCa3.1 blockers on TGFβ1-dependent αSMA protein
expression in HLMFs.
Flow cytometry was used to examine αSMA expres-
sion in HLMFs following 24 h of TGFβ1-stimulation in
the presence of KCa3.1 channel blockers. TGFβ1 signifi-
cantly increased αSMA protein expression in both NFC-
and IPF-derived myofibroblasts (P = 0.0156, Wilcoxon
signed rank test). TRAM-34 (20 and 200 nM) and ICA-
17043 (10 and 100 nM) both dose-dependently
decreased TGFβ1-dependent αSMA expression when
examined by the fold change in geometric mean fluores-
cent intensity, P = 0.0052 and P = 0.0278, respectively
(one-way ANOVA) (Figure 6A, B, C). This indicates a
Figure 4 TGFβ1-dependent Smad2/3 nuclear translocation is Ca2+ dependent. (A) The ratio of nuclear to whole cell TGFβ1-induced
Smad 2/3 nuclear translocation is significantly attenuated when cells are incubated in media without Ca2+ (NFC n = 3, IPF n = 3, data pooled).
(B) Fluorescent microscopy images illustrating the increased nuclear translocation of total Smad2/3 following TGFβ1 stimulation and its movement into
the nucleus, which was significantly attenuated in the absence of Ca2+. Results are represented as mean ± SEM *P < 0.001 (repeated measures ANOVA
corrected by Sidaks multiple comparison test).
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like phenotype, which would explain the reduced
contraction, secretion and proliferative abilities demon-
strated in previously published work [29].
Discussion
This study demonstrates that Ca2+ and the Ca2+-acti-
vated K+ channel KCa3.1 play a key role in the TGFβ1-
dependent activation of Smad2/3 in HLMFs. Inhibition
of KCa3.1 channels therefore attenuates TGFβ1-
dependent gene transcription, resulting in the inhibition
of pro-fibrotic HLMF activity [30] and de-differentiation
of HLMFs towards a fibroblast phenotype as indicated
by a reduction in αSMA protein.
This paper provides mechanistic insight into the in-
hibitory effects of KCa3.1 blockers on HLMF pro-fibrotic
function. Open K+ channels hyperpolarize the plasma
membrane and increase Ca2+ entry following receptor-
dependent cell activation [29,33]. We have demon-
strated previously that blocking KCa3.1 channels
reduces constitutive αSMA expression and Smad2/3
nuclear localization in NFC- and IPF-derived HLMFs,
although it was not possible to detect Smad2/3 phos-
phorylation under these conditions [30]. We have also
shown previously that KCa3.1 activity is required for a
rise in intracellular Ca2+ that occurs following exposureof HLMFs to TGFβ1 [29]. Importantly, here, we have
shown that extracellular Ca2+ and KCa3.1 activity are
required for the TGFβ1-dependent phosphorylation
and nuclear translocation of Smad2/3, an essential ini-
tial step in Smad2/3 activation. Thus, there is a clear
mechanistic link between KCa3.1 activity and Smad2/3-
dependent cell signalling. Although other signalling
cascades including ras/MEK/ERK and P38 MAPK are
also involved in TGFβ1 pro-fibrotic signalling, our data
nevertheless suggest that the predominant regulation of
the TGFβ1 signalling pathway by KCa3.1 channels
occurs proximally at or above the level of Smad2/3
phosphorylation, via effects on Ca2+ signalling.
This study both supports and extends the work of
others investigating the role of KCa3.1 in renal fibrosis
[34], liver fibrosis [35] and brain pathology [36]. Murine
renal fibroblast proliferation and kidney fibrosis follow-
ing ureteric obstruction were significantly attenuated by
KCa3.1 blockers [37], while in a streptazocin mouse
model of diabetes-induced renal fibrosis, KCa3.1 inhib-
ition reduced TGFβ1, TGFBRII and phosphoSmad2/3
expression in the tissue [34,38]. Subsequent work from
the same authors using human renal interstitial fibro-
blasts showed that TGFβ1-dependent increases in types
I and IV collagen and αSMA mRNA expression were at-
tenuated by KCa3.1 blockade, although there was only a
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Figure 5 TGFβ1-dependent transcription of αSMA, collagen type I and KCa3.1 is KCa3.1 dependent. (A) TGFβ1 stimulation significantly
increased αSMA and collagen I mRNA expression in HLMFs per 103 copies of β-Actin, which was significantly inhibited by TRAM-34 200 nM (NFC
n = 4, IPF n = 4, data pooled for statistical analysis). (B) Similarly, ICA-17043 (100 nM) also significantly decreased TGFβ1-dependent increases in
αSMA and collagen I mRNA expression in HLMFs (NFC n = 3, IPF n = 3, data pooled). Results are represented as mean ± SEM or median (IQR)
***P < 0.001 (one sample t test), #P < 0.05 and ##P < 0.01 (paired t test or Wilcoxon signed rank test). (C, D) The fold change of TGFβ1-dependent
KCa3.1 mRNA expression was significantly higher in IPF HLMFs compared to that in NFC HLMFs,
#P = 0.0313 (NFC n = 4, IPF n = 4, data pooled for
statistical analysis). This TGFβ1 dependent increase in KCa3.1 mRNA in IPF donors was significantly attenuated by KCa3.1 channel blockers,
TRAM-34 and ICA-17043 (*P = 0.0385 and P = 0.0313, respectively, paired t test).
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ported [34]. In contrast, we found clear evidence of re-
duced collagen type I mRNA expression in keeping with
previous observations that KCa3.1 blockade attenuates
TGFβ1-dependent HLMF collagen secretion [29] and
that fibroblasts lacking the Smad3 gene have reduced in-
duction of collagen type I gene [39]. We also found that
TGFβ1-dependent αSMA gene transcription was inhib-
ited by KCa3.1 blockers, and TGFβ1-dependent HLMF
αSMA protein expression were reduced. In keeping with
the work of Huang et al., we also found that TGFβ1-
dependent phosphorylation of Smad2/3 was attenuatedFigure 6 TGFβ1-dependent αSMA protein expression is attenuated by
expression in HLMFs show that the fold change in gMFI was significantly in
statistical analysis). TRAM-34 (20 and 200nM) dose-dependently decreased
100nM) significantly reduced TGFβ1-induced αSMA expression. (C) Represe
under the above conditions. Results are represented as mean ± SEM. #P <
comparisons test).by KCa3.1 blockade [38], but in addition show that this
prevents Smad2/3 nuclear translocation.
It is important that we have demonstrated the effects
of KCa3.1 inhibition in parenchymal HLMFs because of
the functional heterogeneity evident in fibroblasts from
different tissues and between species [40-42]. Moreover,
in previous studies of renal fibroblasts, the concentration
of TRAM-34 (2 μM) used was relatively high [38]. We
used two distinct KCa3.1 blockers at the IC50 (20 nM for
TRAM-34 and 10 nM for ICA-17043) and at 10× the
IC50 where >95% of channels will be blocked and found
clear evidence for activity of these drugs at theseKCa3.1 channel block. (A) Flow cytometry measurements of αSMA
creased by TGFβ1 (10 ng/ml) (NFC n = 3, IPF n = 4, data pooled for
TGFβ1-induced αSMA expression. (B) Similarly, ICA-17043 (10 and
ntative fluorescent histogram showing αSMA expression in HLMFs
0.05 (paired t test); *P < 0.05, **P < 0.01 (corrected by Dunn’s multiple
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concentration of ICA-17043 used here can be achieved
in vivo with oral dosing [43], although the free drug con-
centration will be reduced due to protein binding. Thus,
pharmacological activity is likely to be achieved within
human lung following oral administration.
We found previously that KCa3.1 inhibition reduced
TGFβ1-dependent HLMF contractility in collagen gels
[29]. Our demonstration that this is associated with re-
duced αSMA gene transcription and protein expression
suggests that de-differentiation towards a fibroblast
phenotype with reduced contractile machinery may ex-
plain this reduced contractility, at least in part. However,
attenuation of Ca2+ influx as demonstrated previously
[29], with depolarization of the plasma membrane could
also contribute to the effects of KCa3.1 blockade on
HLMF contraction.
Our findings also provide a potential mechanism
for the ability of KCa3.1 inhibition to prevent airway
wall remodelling in a mouse model of asthma [44].
That study demonstrated that treatment with TRAM-
34 reduced airway smooth muscle mass, peribron-
chial fibrosis, and sub-epithelial collagen expression.
While these effects might have occurred in part
through the inhibition of the associated inflammatory
response, it seems likely that a direct effect on air-
way smooth muscle and myofibroblast activity was
also relevant.Conclusions
Myofibroblast activity is clearly a key driver of tissue fi-
brosis and shrinkage in IPF [45-47]. There is strong evi-
dence that TGFβ1-dependent signalling contributes to
this fibrotic process [12,14,20,30,38,48]. However, there
is also evidence that HLMFs derived from IPF lungs
also exhibit greater constitutive pro-fibrotic activity,
which might occur due to pre-programming by genet-
ics, and/or re-programming by epigenetics [30,49]. Im-
portantly, KCa3.1 blockade is able to inhibit both
TGFβ1-dependent and constitutive pro-fibrotic HLMF
activity as shown here and in our previous study [30],
respectively. This provides further support for the view
that KCa3.1 may provide a novel and effective target for
the treatment of IPF. Furthermore, the capacity for
KCa3.1 inhibition to downregulate TGFβ1-dependent
increases in KCa3.1 expression suggests that inhibiting
KCa3.1 will rapidly downregulate the TGFβ1 axis
through positive feedback (Figure 7). KCa3.1 knockout
animals are relatively healthy, and an oral KCa3.1 in-
hibitor, ICA-17043 (Senicapoc), was well tolerated for
12 months in a phase III clinical trial of sickle cell dis-
ease [43]. There is therefore the potential for the rapid
translation of KCa3.1-directed therapy to the clinic.Methods
Ethics statement
All patients donating tissue gave written informed con-
sent, and the study was approved by the National
Research Ethics Service (references 07/MRE08/42 and
10/H0402/12).
Human lung myofibroblasts isolation and culture
NFC parenchymal HLMFs were derived from healthy
areas of lung from patients undergoing lung resection
for carcinoma at Glenfield Hospital, Leicester, UK. No
morphological evidence of disease was found in the tis-
sue samples used for HLMF isolation. IPF HLMFs were
derived from patients undergoing lung biopsy for diag-
nostic purposes at the University of Pittsburgh Medical
Center, USA, and were shown to have UIP on histo-
logical examination. HLMFs were grown from explanted
lung tissue from both sources under identical conditions,
using Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), anti-
biotic/antimycotic agents and non-essential amino acids
[50,51]. The cells were cultured at 37°C in 5% CO2/95%
air. The cells were studied at passages 4 to 5 for func-
tional studies. Myofibroblasts were characterized as pre-
viously described [29]. All NFC patients gave informed
written consent, and the study was approved by the
Leicestershire, Northamptonshire and Rutland Re-
search Ethics Committee 2. Written informed consent
was also obtained from all IPF subjects, in accordance
with the responsible University of Pittsburgh Institu-
tional Review Board.
Flow cytometry
HLMFs were grown on T25 flasks and serum starved for
24 h prior to the experiment. The HLMFs were either
left unstimulated or stimulated for 24 h with TGFβ1 (10
ng/ml), in the presence of 0.1% DMSO control, TRAM-
34 (200 nM) or ICA-17043 (100 nM). The cells were
detached using 0.1% trypsin/0.1% EDTA, washed then
fixed and permeabilized in 4% paraformaldehyde plus
0.1% saponin (Sigma-Aldrich, St. Louis, MO, USA),
respectively, for 20 min on ice. Myofibroblasts were la-
belled with FITC-conjugated mouse monoclonal anti-
αSMA (Sigma-Aldrich, St. Louis, MO, USA), indirectly
labelled with FITC and isotype control FITC-conjugated
mouse IgG2a. Secondary antibodies labelled with FITC
(F0313, Dako, Glostrup, Denmark) were applied. Ana-
lysis was performed using single colour flow cytometry
on a FACScan (BD, Oxford, UK).
qRT-PCR
HLMF RNA was isolated using the RNeasy Plus Kit
(Qiagen, West Sussex, UK) according to the manufac-
turer’s instructions. Primers were designed for ACT2A,
Figure 7 The involvement of KCa3.1 in the TGF/Smad 2/3 signalling pathway. A diagrammatic representation of how Smad2/3 phosphorylation
and subsequent nuclear translocation is reliant on an influx of extracellular Ca2+ and KCa3.1 ion channels. TGFβ1 stimulation triggers an influx
of extracellular Ca2+, which in turns opens Ca2+-activated KCa3.1 K
+ channels. KCa3.1 opening maintains a negative membrane which in turn
promotes Ca2+ entry. Phosphorylation of Smad2/3 and therefore its downstream effects such as translocation and gene transcription are heavily reliant
on Ca2+. KCa3.1 channel inhibition reduces Ca
2+ entry, which in turn reduces Smad2/3 phosphorylation and nuclear translocation, and thus reduces
TGFβ1-dependent gene transcription.
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GAAGGAATAGCCACGCTCAG, product size 222 bp
from NCB1 Reference sequence NM_001141945.1 and
COL1A1, forward TTCTGCAACATGGAGACTGG and
reverse CGCCATACTCGAACTGGAATC, product size
151 bp from reference sequence NM_000088.3. KCa3.1
and β-actin primers were analysed using gene-specific
Quantitect Primer Assay primers (Qiagen, Hilden,
Germany), Hs_KCNN4_1_SG and HS_ACTB_1_SG. All
experiments were performed in duplicate. All expres-
sion data was normalized to β-actin and corrected
using the reference dye ROX. Gene expression was
quantified by real-time PCR using the Brilliant SYBR
Green QRT-PCR 1-Step Master Mix (Stratagene, Breda,
The Netherlands). PCR products were run on a 1.5%
agarose gel to confirm the product amplified was the
correct size, and they were sequenced to confirm the
specificity of the primers. Prior to qRT-PCR, myofibro-
blasts were grown to confluence, serum starved for 24
h and then stimulated with TGFβ1 (10 ng/ml) in the
presence of 0.1% DMSO control, TRAM-34 (200 nM)
or ICA-17043 (100 nM).Western blot for SMAD proteins
Cells were grown in T75 flasks, serum starved for 24 h and
stimulated with TGFβ1 (10 ng/ml) in the presence of either
0.1% DMSO control, TRAM-34 (200 nM), ICA-17043 (100
nM) or Ca2+-free media for 1 h. The cells were detached
with 0.1% Trypsin/EDTA and washed. The protein was
isolated using RIPA buffer lysis system (Santa Cruz,
Heidelberg, Germany), and the total protein concentration
was determined using the DC Bio-Rad protein Assay (Bio-
Rad, Hemel Hempstead, UK). Of the protein, 30 μg was re-
solved using 10% Mini-Protean TGX precast gels (Bio-Rad,
Hemel Hempstead, UK) and then transferred to an
immunobilon-P polyvinylidene difluoride membrane,
using Trans-blot Turbo transfer packs (Bio-Rad, Hemel,
Hemopstead, UK). The membranes were blocked with 5%
milk and incubated with rabbit monoclonal anti-phospho-
Smad2/Smad3 (0.231 μg/ml, Cell Signalling, Danvers, MA,
USA) or rabbit monoclonal anti-smad2/smad3 (0.0087 μg/
ml, Cell Signalling). Protein bands were identified by horse-
radish peroxidase-conjugated secondary antibody and
enhanced chemiluminescence reagent (Amersham Labora-
tories, Buckinghamshire, UK). Immunolabelled proteins
Roach et al. Fibrogenesis & Tissue Repair  (2015) 8:5 Page 11 of 12were visualized using ImageQuant LAS 4000 (GE Health-
care Life Sciences, Buckinghamshire, UK).
SMAD nuclear translocation
HLMFs were grown on 8-well chamber slides and
serum-starved for 24 h prior to the experiment. The
cells were then stimulated with TGFβ1 (10 ng/ml) in the
presence of either 0.1% DMSO control, TRAM-34 (200
nM), ICA-17043 (100 nM), TRAM-85 (200nM) or
Ca2+-free media. After 1 h, the cells were fixed with
methanol for 20 min on ice, blocked using 3% BSA for
1 h and immunostained using rabbit monoclonal anti-
Smad2/Smad3 (0.174 μg/ml, Cell Signalling). Secondary
antibody labelled with FITC (F0313, Dako) was applied,
and the cells counterstained with 4′,6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO,
USA). The cells were mounted with fluorescent mount-
ing medium and cover-slipped.
Original images were captured on an epifluorescent
microscope (Olympus BX50, Olympus UK Ltd., Southend-
on-sea, Essex, UK); grey scale intensity was examined using
Cell F imaging software (Olympus UK Ltd., Essex, UK).
Matched exposures were used for isotype controls. The in-
tensity of nuclear Smad2/3 staining was quantified by
measuring the grey scale intensity of DAPI positive nuclei
with a minimum of 10 random cells measured in one field
for each condition.
Nuclear fraction
NFC and IPF-derived HLMFs were grown in T75 flasks,
serum-starved for 24 h then stimulated with TGFβ1 (10
ng/ml) in the presence of either 0.1% DMSO control,
TRAM-34 (200 nM) or ICA-17043 (100 nM). After 1 h,
HLMF were detached with 0.1% Trypsin/EDTA and
washed. Nuclear and cytoplasmic extracts were isolated
using the Nuclear Extract Kit (Abcam, ab113474, New
territories, Hong Kong). Proteins of both the nuclear
and cytoplasmic extracts were then isolated using the
RIPA buffer lysis system and the concentration deter-
mined using the DC Bio-Rad protein Assay. Western
blot was then performed as described above.
Statistical analysis
Experiments from an individual donor were performed
either in duplicate or triplicate, and a mean value was
derived for each condition. Data distribution across do-
nors was tested for normality using the Kolmogorov-
Smirnov test. For parametric data, the one-way ANOVA
or repeated measures ANOVA for across-group compar-
isons was used followed by the appropriate multiple
comparison post hoc test; otherwise, an unpaired or
paired t test was used. Where appropriate, a one sample
t test was used using a null hypothesis of 1. For non-
parametric data, the Friedman test was used for acrossgroup comparisons followed by the appropriate multiple
comparison post hoc test, or the Mann Whitney U test
was used where there were two unpaired groups. Graph-
Pad Prism for windows (version 6, GraphPad Software,
San Diego, CA, USA) was used for these analyses. A
value of P < 0.05 was taken to assume statistical signifi-
cance and data are represented as mean (± SEM) or
median (IQR).
Abbreviations
DMEM: Dulbecco’s modified eagle’s medium; FBS: Fetal bovine serum;
HLMF: Human lung myofibroblast; IPF: Idiopathic pulmonary fibrosis;
IQR: Interquartile range; NFC: Non-fibrotic control; SEM: Standard error of the
mean; TGFβ1: Transforming growth factor beta 1; TGFβRII: Transforming
growth factor beta receptor II; αSMA: α-smooth muscle actin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KMR performed all of the laboratory studies on human lung myofibroblasts
under the supervision of PB, analysed the data and drafted the manuscript.
CFB recruited and characterized patients with IPF for inclusion in the study,
advised on myofibroblast cell culture, analysed and interpreted the data and
revised the manuscript critically for intellectual content. HW provided TRAM-34
for the in vitro studies, analysed and interpreted the data and revised the
manuscript critically for intellectual content. PB, YA and KMR conceived
and designed the research, analysed the data and drafted the manuscript.
All authors approved the final manuscript.
Acknowledgements
This work was supported by The Dunhill Medical Trust, project grant R270/
1112. The work was also supported in part by the National Institute for
Health Research Leicester Respiratory Biomedical Research Unit. The views
expressed are those of the author(s) and not necessarily those of the NHS,
the NIHR or the Department of Health. HW was supported by RO1 GM076063
from the National Institute of Health. The funders had no role in study design,
data collection and analysis, decision to publish or preparation of the
manuscript.
Author details
1Department of Infection, Immunity and Inflammation, Institute for Lung
Health, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3
9QP, UK. 2Department of Medicine, Division of Rheumatology and
Immunology, University of South Carolina, Columbia, SC 29208, USA.
3Department of Pharmacology, University of California, 451 Health Sciences
Drive, Davis, CA 95616, USA.
Received: 10 December 2014 Accepted: 5 March 2015
References
1. Raghu G, Masta S, Meyers D, Narayanan AS. Collagen synthesis by normal
and fibrotic human lung fibroblasts and the effect of transforming growth
factor-beta. Am Rev Respir Dis. 1989;140(1):95–100.
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and
prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
2006;174(7):810–6.
3. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and
mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax.
2006;61(11):980–5.
4. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D,
et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):
two randomised trials. Lancet. 2011;377(9779):1760–9.
5. Carter NJ. Pirfenidone in idiopathic pulmonary fibrosis. Drugs. 2011;71(13):1721–32.
6. King TEJ, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK,
et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary
fibrosis. N Engl J Med. 2014;370(22):2083–92.
Roach et al. Fibrogenesis & Tissue Repair  (2015) 8:5 Page 12 of 127. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates
latent tgf-beta1 from the extracellular matrix. J Cell Biol. 2007;179:1311–23.
8. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol.
1994;124(4):401–4.
9. Gabbiani G, Ryan GB, Majno G. Presence of modified fibroblasts in granulation
tissue and their possible role in wound contraction. Experientia. 1971;27:5.
10. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming
growth factor beta(1). Am J Respir Cell Mol Biol. 1999;21:6.
11. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation
and survival in Thy-1(−) lung fibroblasts. Am J Respir Cell Mol Biol.
2007;36(2):226–35.
12. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect. 1999;1(15):1349–65.
13. Raghu G, Masta S, Meyers D, Narayanan AS. Collagen synthesis by normal
and fibrotic human lung fibroblasts and the effect of transforming growth
factor-β. Am J Respir Crit Care Med. 1989;140(1):95–100.
14. Khalil N, Oconnor R, Unruh H, Warren P, Flanders K, Kemp A, et al. Increased
production and immunohistochemical localization of transforming
growth-factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol
Biol. 1991;5(2):155–62.
15. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. Abrogation of
TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase
inhibition. Am J Physiol Lung Cell Mol Physiol. 2009;297(5):L864–70.
16. Moustakas A, Pardali K, Gaal A, Heldin C. Mechanisms of TGF-β signaling in
regulation of cell growth and differentiation. Immunol Lett. 2002;82(1–2):85–91.
17. Khouw IMSL, van Wachem PB, Plantinga JA, Vujaskovic Z, Wissink MJ, de Leij
LFMH, et al. TGF-β and bFGF affect the differentiation of proliferating
porcine fibroblasts into myofibroblasts in vitro. Biomaterials. 1999;20(19):1815–22.
18. Mattey DL, Dawes PT, Nixon NB, Slater H. Transforming growth factor beta 1
and interleukin 4 induced alpha smooth muscle actin expression and
myofibroblast-like differentiation in human synovial fibroblasts in vitro:
modulation by basic fibroblast growth factor. Ann Rheum Dis. 1997;56(7):426–31.
19. Attisano L, Wrana JL. Signal transduction by the TGF-ß superfamily. Science.
2002;296(5573):1646–7.
20. Gu L, Zhu Y, Yang X, Guo Z, Xu W, Tian X. Effect of TGF-beta/Smad signaling
pathway on lung myofibroblast differentiation. Acta Pharmacol Sin.
2007;28(3):382–91.
21. Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-beta-
induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol.
2003;29:3.
22. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, et al.
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
EMBO J. 1997;16(17):5353–62.
23. Fanger C, Rauer H, Neben A, Miller M, Rauer H, Wulff H, et al.
Calcium-activated potassium channels sustain calcium signaling in T
lymphocytes - selective blockers and manipulated channel expression
levels. J Biol Chem. 2001;276(15):12249–56.
24. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. Design of
a potent and selective inhibitor of the intermediate-conductance Ca2+-activated
K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A.
2000;97(14):8151–6.
25. Duffy S, Berger P, Cruse G, Yang W, Bolton SJ, Bradding P. The K+ channel
iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells.
J Allergy Clin Immunol. 2004;114(1):66–72.
26. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, et al.
Up-regulation of the IKCa1 potassium channel during T-cell activation.
Molecular mechanism and functional consequences. J Biol Chem.
2000;275(47):37137–49.
27. Cruse G, Duffy SM, Brightling CE, Bradding P. Functional KCa3.1 K+ channels
are required for human lung mast cell migration. Thorax. 2006;61(10):880–5.
28. Bradding P, Wulff H. The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets
for asthma therapy. Br J Pharmacol. 2009;157(8):1330–9.
29. Roach K, Duffy S, Coward W, Feghali-Bostwick C, Wulff H, Bradding P.
The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis.
PLoS One. 2013;8(12):e85244.
30. Roach KM, Wulff H, Feghali-Bostwick C, Amrani Y, Bradding P. Increased
constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis
myofibroblasts is KCa3.1-dependent. Respir Res. 2014;15:155. doi:10.1186/
s12931-014-0155-5.
31. Zhao J, Shi W, Wang Y, Chen H, Bringas PJ, Datto MB, et al. Smad3
deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J
Physiol Lung Cell Mol Physiol. 2002;282(3):585–93.32. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard
Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled
red blood cell dehydration in vitro and in vivo in SAD mice. Blood.
2003;101(6):2412–8.
33. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium
signalling. Nat Rev Mol Cell Biol. 2000;1(1):11–21.
34. Huang C, Shen S, Ma Q, Gill A, Pollock CA, Chen X. KCa3.1 mediates
activation of fibroblasts in diabetic renal interstitial fibrosis. Nephrol Dial
Transplant. 2014;29(2):313–24.
35. Freise C, Heldwein S, Erben U, Hoyer J, Köhler R, Jöhrens K, et al. K+-channel
inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis
associated characteristics of hepatic stellate cells. Liver Int. 2014;35(4):1244–52.
36. Yu Z, Yu P, Chen H, Geller HM. Targeted inhibition of KCa3.1 attenuates
TGF-beta-induced reactive astrogliosis through the Smad2/3 signaling
pathway. J Neurochem. 2014;130(1):41–9.
37. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, et al. Renal fibrosis is
attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl
Acad Sci U S A. 2009;106(34):14518–23.
38. Huang C, Shen S, Ma Q, Chen J, Gill A, Pollock CA, et al. Blockade of KCa3.1
ameliorates renal fibrosis through the TGF-beta1/Smad pathway in diabetic
mice. Diabetes. 2013;62(8):2923–34.
39. Chen SJ, Yuan WH, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation
of type I collagen transcription in human skin fibroblasts by TGF-beta:
involvement of Smad 3. J Invest Dermatol. 1999;112(1):49–57.
40. Kotaru C, Schoonover KJ, Trudeau JB, Huynh ML, Zhou X, Hu H, et al.
Regional fibroblast heterogeneity in the lung: implications for remodeling.
Am J Respir Crit Care Med. 2006;173(11):1208–15.
41. Kishaba Y, Matsubara D, Niki T. Heterogeneous expression of nestin in
myofibroblasts of various human tissues. Pathol Int. 2010;60(5):378–85.
42. Zhou X, Wu W, Hu H, Milosevic J, Konishi K, Kaminski N, et al. Genomic
differences distinguish the myofibroblast phenotype of distal lung from
airway fibroblasts. Am J Respir Cell Mol Biol. 2011;45(6):1256–62.
43. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O,
et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043),
in patients with sickle cell anemia. Blood. 2008;111(8):3991–7.
44. Girodet P, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau A, et al. Ca2
+-Activated K+ Channel-3.1 Blocker TRAM-34 attenuates airway remodeling
and eosinophilia in a murine asthma model. Am J of Respir Cell Mol Biol.
2013;48(2):212–9.
45. McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role
in disease. Int J Biochem Cell Biol. 2007;39(4):666–71.
46. Tomasek J, Gabbiani G, Hinz B, Chaponnier C, Brown R. Myofibroblasts and
mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol.
2002;3(5):349–63.
47. Phan SH. The myofibroblast in pulmonary fibrosis. Chest. 2002;122(6
Suppl):286S–9.
48. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for
fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–34.
49. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone
acetylation is responsible for the diminished expression of cyclooxygenase
2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009;29(15):4325–39.
50. Keira SM, Ferreira LM, Gragnani A, Duarte IS, Santos A. Anunciação Neves
dos I. Experimental model for fibroblast culture. Acta Cir Bras. 2004;19:11–6.
51. Pilewski JM, Liu LX, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like
growth factor binding proteins 3 and 5 are overexpressed in idiopathic
pulmonary fibrosis and contribute to extracellular matrix deposition. Am J
Pathol. 2005;166(2):399–407.
